Mitral valve annuloplasty double by the year 2030. Every year, 300,000 people worldwide undergo open heart surgery for mitral valve repair, 44,000 people in the US alone. Since it was initially established 40 years ago by Professor Alain Carpentier, mitral valve annuloplasty has been continuously improved and is considered the gold standard for the treatment of most etiologies of mitral valve dysfunction today. The goal of mitral valve annuloplasty is to regain mitral valve competence by restoring the physiological form and function of the normal mitral valve apparatus. Under normal conditions the mitral valve undergoes significant dynamic changes in shape and size throughout
Mitral valve prolapse with palpitations, atypical chest pain, dyspnea on exertion, low body mass index, and electrocardiogram abnormalities in the setting of anxiety, syncope, low blood pressure, Migraine-Like Headache, orthostatic hypotension, lightheadedness, and other signs suggestive of autonomic nervous system dysfunction (dysautonomia). Mitral valve prolapse is frequently associated with mild mitral regurgitation, where blood aberrantly flows from the left ventricle into the left atrium during systole. In the United States, MVP is the most common cause of severe, non-ischemic mitral regurgitation. This is occasionally due to rupture of the chordae tendineae that support the mitral valve. MVP may occur with greater frequency in